Literature DB >> 7661940

A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.

R C Inhorn1, J C Aster, S A Roach, C A Slapak, R Soiffer, R Tantravahi, R M Stone.   

Abstract

We report two patients with a distinctive biphenotypic hematologic disorder characterized by lymphoblastic lymphoma (LBL), eosinophilia, and myeloid malignancy and/or hyperplasia associated with a t(8;13)(p11;q11) chromosomal translocation in both bone marrow and lymph node specimens. Both patients presented with lymphadenopathy pathologically classified as LBL with a T-cell immunophenotype, myeloid hyperplasia of the bone marrow, and peripheral blood eosinophilia. The first patient achieved clinical complete remission after receiving several regimens of chemotherapy and remains disease-free 16 months after undergoing allogeneic bone marrow transplantation. The second patient developed progressive lymphadenopathy despite several courses of chemotherapy directed against non-Hodgkin's lymphoma. Eight months after his initial presentation, he developed acute myelogenous leukemia that was refractory to therapy. Comparison of these patients with four similar cases recently reported in the literature suggests that this constellation of findings constitutes a distinctive clinicopathologic syndrome. Molecular analysis of the t(8;13) translocation breakpoint may identify genes located in this region and provide insight into the pathogenesis of this interesting biphenotypic hematologic malignancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661940

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Cardiac disease in a case of precursor B acute lymphoblastic leukaemia with eosinophilia(ALL/Eo).

Authors:  Mehrnaz Asadi Gharabaghi; Pegah Aghajanzadeh; Ghazal Zahedi; Roghayyeh Borji; Leila Derakhskan; Roya Sattarzadeh; Ramezanali Sharaifian
Journal:  BMJ Case Rep       Date:  2012-01-20

2.  Mediastinal Mass with Hyper-eosinophilia in a Young Boy -A Diagnostic Dilemma.

Authors:  Abdul Shahid Poovathum Parambil; Shruti Prem; Priya Mary Jacob; Rekha Appukuttan Nair
Journal:  J Clin Diagn Res       Date:  2016-07-01

3.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

5.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).

Authors:  C Popovici; J Adélaïde; V Ollendorff; M Chaffanet; G Guasch; M Jacrot; D Leroux; D Birnbaum; M J Pébusque
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma.

Authors:  Igor Buchwalow; Dmitri Atiakshin; Vera Samoilova; Werner Boecker; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2017-12-02       Impact factor: 4.304

7.  Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Authors:  Ritsuro Suzuki; Makoto Murata; Masahiro Kami; Shigeki Ohtake; Norio Asou; Yoshihisa Kodera; Masao Tomonaga; Yasufumi Masaki; Shuya Kusumoto; Jin Takeuchi; Shin Matsuda; Hisamaru Hirai; m Seiichi Yorimitsu; Nobuyuki Hamajima; Masao Seto; Masanori Shimoyama; Ryuzo Ohno; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Authors:  Mingqiang Ren; Haiyan Qin; Eiko Kitamura; John K Cowell
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.